EUVIMEDEUVIMED entdecken
Crossref

Eye‐sparing treatment for sinonasal tumors invading the orbit in the era of personalized therapy

Jie Wang, Li Wang, Tian Wang iD, Tianci Tang, Yi Li, Qiang Li, Xinmao Song

International Journal of Cancer · 2025

DOI: 10.1002/ijc.35395 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Jie Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Eye & ENT Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Paranasal Sinus Neoplasms, Organ Sparing Treatments, Precision Medicine, Orbital Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Few studies investigated the eye‐sparing treatment in patients with sinonasal carcinomas (SNCs) from the perspective of modern precision radiation, and the eye‐sparing treatment in patients with grade III orbital invasion was rarely discussed. This retrospective study included patients with primary SNCs who accepted eye‐sparing treatment from October 2000 to June 2022 at a single institution. Patients' clinical information and follow‐up data (including visual data) were obtained. All patients underwent radio(chemo)therapy alone or with surgery. The primary outcomes were overall survival (OS) and progression‐free survival (PFS) rates. Secondary outcomes included regional‐failure‐free survival (RFS) and distant metastasis‐free survival (DMFS) rates. 42.7% of SNC patients (430/1006) had orbital invasion. Orbital invasion significantly decreased the 5‐year OS (77.9% vs. 61.1%, p < .001), PFS (70.5% vs. 51.3%, p < .001), RFS (77.8% vs. 60.8%, p < .001), and DMFS (76.8% vs. 59.3%, p < .001), which worsened as the invasion grade increased. Stratified analysis by treatment indicated that surgery significantly improved the OS ( p < .001) and PFS ( p = .0031) in patients with grade I/II orbital invasion. In contrast, surgery conferred no benefits to OS ( p = .14) and PFS ( p = .16) in patients with grade III orbital invasion. Blindness occurred in 6.7% of patients with orbital involvement and 1.9% of patients without orbital involvement. There was no difference in the blindness ratio among different treatment modes ( χ 2 = 2.35, p = .31). Orbital invasion predicted poor survival outcomes, which worsened as the invasion grade increased. Surgery combined with radio(chemo)therapy was preferred in patients with grade I/II orbital invasion; however, surgery may have a limited effect on the survival of patients with grade III orbital invasion.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Paranasal Sinus NeoplasmsOrgan Sparing TreatmentsPrecision MedicineOrbital NeoplasmsOrbitHumansMaleFemaleMiddle AgedRetrospective StudiesAgedAdultNeoplasm InvasivenessAged, 80 and overChemoradiotherapyProgression-Free SurvivalFollow-Up Studies

Stichwörter der Autor:innen

eye‐sparing treatmentorbital invasionradiotherapysinonasal carcinomassurgery

Autor:innen und Institutionen

  • Department of Radiation Oncology, Eye & ENT Hospital, Fudan University, Shanghai, China.
  • Department of Oncology, 920th Hospital of Joint Logistics Support Force, Kunming, China.
  • Department of Otorhinolaryngology, Jinshan Hospital Affiliated to Fudan University, Shanghai, China.

ORCID-Profile: Tian Wang

Zitieren

APA

Wang, J., Wang, L., Wang, T., Tang, T., Li, Y., Li, Q., & Song, X. (2025). Eye‐sparing treatment for sinonasal tumors invading the orbit in the era of personalized therapy. International Journal of Cancer. https://doi.org/10.1002/ijc.35395

Vancouver

Wang J, Wang L, Wang T, Tang T, Li Y, Li Q, et al. Eye‐sparing treatment for sinonasal tumors invading the orbit in the era of personalized therapy. International Journal of Cancer. 2025. doi:10.1002/ijc.35395

BibTeX
@article{Wang2025,
  author = {Wang, Jie and Wang, Li and Wang, Tian and Tang, Tianci and Li, Yi and Li, Qiang and Song, Xinmao},
  title = {Eye‐sparing treatment for sinonasal tumors invading the orbit in the era of personalized therapy},
  journal = {International Journal of Cancer},
  year = {2025},
  doi = {10.1002/ijc.35395}
}
Kostenlos starten →